Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects (BE)
A Single Center, Open Label, Randomized, Single-dose, Two-period, Two-way Cross-over Study to Compare the Rate and Extent of Absorption of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects.
Sponsor: Center for Bioequivalence Studies and Clinical Research
A PHASE1 clinical study on Bioequivalence Study and Healthy Individuals, this trial is completed. The trial is conducted by Center for Bioequivalence Studies and Clinical Research and has accumulated 6 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Dec 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2021 — Sep 2022 [monthly]
Completed PHASE1
Status: Not Yet Recruiting → Completed
▶ Show 1 earlier version
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
May 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Center for Bioequivalence Studies and Clinical Research
- SAMI Pharmaceuticals (Pvt.) Ltd.
- University of Karachi
For direct contact, visit the study record on ClinicalTrials.gov .